

Report of the Directors  
Audited Financial Statements

RARE DISEASE HONG KONG LIMITED  
(Incorporated in Hong Kong with limited liability)

31 December 2024

**LSW** LEE SIK WAI & CO.  
Certified Public Accountants

李式帷會計師事務所

RARE DISEASE HONG KONG LIMITED

<b><u>CONTENTS</u></b>	<b><u>PAGES</u></b>
Report of the directors	1 – 2
Independent auditor's report	3 – 5
Income Statement	6
Statement of financial position	7
Accounting policies and explanatory notes to the financial statements	8 – 12

RARE DISEASE HONG KONG LIMITED  
(incorporated in Hong Kong with liabilities limited by guarantee)

REPORT OF THE DIRECTORS

The directors present the audited financial statements of Rare Disease Hong Kong Limited (“the Company”) for the year ended 31 December 2024.

**Principal activities**

The Company is engaged in providing education and a platform, in order to increase public awareness of rare diseases, strengthen exchanges, support and assist in the study of rare diseases.

**Result of operation**

The financial performance for the year ended 31 December 2024 and the financial position of the Company at that date are set out in the financial statements from pages 6 to 12.

**Donations**

During the year, no donation for charitable or other purposes to a total amount of not less than HK\$10,000 was made by the Company.

**Fixed assets**

There are no movements in fixed assets during the year.

**Directors**

The directors who held office during the financial year and up to date of this report were:

CHAN Danny  
CHOW Kuen Tai Ronald  
LEUNG Chat Kan  
TSANG Kin Ping  
TSUI Kong King Helen  
WONG Man Yee  
WONG Yiu Man Davy  
YUEN Pui Ling Rebecca  
HO Ching Sum (appointed on 15 June 2024)  
LEUNG Pui Kei Raymond (appointed on 15 June 2024)  
LAI Ka Wai  
TAM Wing Hang (Deceased on 21 January 2024)  
CHAN Wai Sze (Resigned on 22 January 2024)

In accordance with article 54 and 55 of Articles of Association of the Company, the remaining directors retire at the forthcoming annual general meeting but, being eligible, offer themselves for re-election.

The Company falls within reporting exemption for the financial year.

**RARE DISEASE HONG KONG LIMITED**  
(incorporated in Hong Kong with liabilities limited by guarantee)

**REPORT OF DIRECTORS (continued)**

**Business review**

Pursuant to Section 388(3)(a) of the Hong Kong Companies Ordinance (Cap. 622), that the Company falls within the reporting exemption for the financial year so is not required to prepare a business review to comply with Schedule 5 of the Hong Kong Companies Ordinance for the financial year.

**Management contracts**

No contracts concerning the management and administration of the whole or any substantial part of the business of the Company were entered into or existed during the year.

**Permitted indemnity Provision**

At no time during and after the financial year were there any permitted indemnity provision in force for the benefit of one or more directors of the Company.

**Director's interests**

At no time during the year was the Company a party to any arrangement to enable the director to acquire benefits by means of the acquisition of debentures, if any, of the Company or any other body corporate.

Apart from those transactions disclosed in note 8 to the financial statements, no transaction, arrangement or contract of significance to which the Company was a party and in which a director had a material interest, subsisted at the end of the reporting year or at any time during the year.

**Auditor**

The financial statements for the year have been audited by Lee Sik Wai & Co., who offer themselves for re-appointment.

**Other matters**

At the date of this report, the directors are not aware of any circumstances not otherwise dealt with in this report or financial statements which would render any amount stated in the financial statements misleading.

ON BEHALF OF THE DIRECTORS



---

Tsang Kin Ping  
Director  
Hong Kong  
21 May 2025

## INDEPENDENT AUDITOR'S REPORT

To the members of  
**RARE DISEASE HONG KONG LIMITED**  
(incorporated in Hong Kong with liabilities limited by guarantee)

## REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

### Opinion

We have audited the financial statements of Rare Disease Hong Kong Limited ("the Company") set out on pages 6 to 12, which comprise the statement of financial position as at 31 December 2024, and the income statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements of the Company are prepared, in all material respects, in accordance with the Hong Kong Small and Medium-sized Entity Financial Reporting Standard ("SME-FRS") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the Hong Kong Companies Ordinance.

### Basis for Opinion

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") and with reference to Practice Note 900 (Revised), Audit of Financial Statements Prepared in Accordance with the Small and Medium-sized Entity Financial Reporting Standard issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the HKICPA's Code of Ethics for Professional Accountants ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Other information

The Directors are responsible for the other information. The other information comprises the report of the directors, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## INDEPENDENT AUDITOR'S REPORT

To the members of  
RARE DISEASE HONG KONG LIMITED  
(incorporated in Hong Kong with liabilities limited by guarantee)

### Responsibilities of Directors and Those Charged with Governance for the Financial Statements

The Directors are responsible for the preparation of the financial statements in accordance with the SME-FRS issued by the HKICPA and the Hong Kong Companies Ordinance, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. In addition, we are required to obtain reasonable assurance about whether the financial statements satisfy the requirements of the License Conditions Related to Financial Aspects.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Council of Management.

## INDEPENDENT AUDITOR'S REPORT

To the members of  
RARE DISEASE HONG KONG LIMITED  
(incorporated in Hong Kong with liabilities limited by guarantee)

### Auditor's Responsibilities for the Audit of the Financial Statements (continued)

- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The engagement principal on the audit resulting in this independent auditor's report is Lee Sik Wai, Benjamin (practising certificate number: P01889).

A large, stylized handwritten signature in black ink, appearing to read 'Lee Sik Wai Benjamin'.

***Lee Sik Wai Benjamin***

**Lee Sik Wai & Co.**  
**Certified Public Accountants**  
Hong Kong  
21 May 2025

RARE DISEASE HONG KONG LIMITED

STATEMENT OF INCOME AND RETAINED EARNINGS

For the year ended 31 December 2024

	Notes	2024 HK\$	2023 HK\$
Revenue			
Donations and sponsorship income		4,759,109	4,566,118
Government subvention from SWD		247,870	247,660
Membership fee income		3,220	1,460
	2	<u>5,010,199</u>	<u>4,815,238</u>
Other income			
Bank interest income		10,457	14,920
Loan interests income from a third party		900,000	600,000
Sundry income		19,037	17,300
	2	<u>929,494</u>	<u>632,220</u>
Administrative and operations expenses			
Auditor's remuneration		9,120	-
Advertising and promotion expenses		1,813,928	2,068,635
Bank charges		820	1,335
Computer expenses		5,669	-
Conference and seminars		1,291,865	516,161
Deficits on project grants		109,728	10,183
Grants		273,750	837,742
Insurance		5,026	6,188
Legal and professional fees		105	-
Members' activities expenses		75,951	70,866
MPF		38,152	25,800
Postage, courier charges		488	5,611
Pandemic sponsor expenses		-	912
Printing and stationery		72,097	31,465
Salaries and wages		912,359	756,093
Subscription fee		6,586	-
Sundry expenses		36,436	104,005
Supportive services fees		84,000	84,000
Telecommunication		12,913	-
Training expenses		10,749	5,616
Travelling - local		26,033	19,834
Travelling - overseas		128,161	-
Websites		29,642	50,012
		<u>4,943,578</u>	<u>4,594,458</u>
Surplus for the year	3	<u>996,115</u>	<u>853,000</u>

The notes on pages 8 to 12 form part of these financial statements.



RARE DISEASE HONG KONG LIMITED


STATEMENT OF FINANCIAL POSITION

As at 31 December 2024

	Notes	2024 HK\$	2023 HK\$
<b>CURRENT ASSETS</b>		563,053	618,138
Accounts receivable	6	4,000,000	4,000,000
Loans to a third party		-	292
Prepayments and deposits		4,123,820	2,905,698
Cash and bank balances			
		<u>8,686,873</u>	<u>7,524,127</u>
<b>CURRENT LIABILITIES</b>		396,001	229,580
Other payables and accruals		62,125	61,915
Receipt in advance			
		<u>458,126</u>	<u>291,495</u>
<b>NET CURRENT ASSETS</b>		<u>8,228,747</u>	<u>7,232,632</u>
<b>NET ASSETS</b>		<u>8,228,747</u>	<u>7,232,632</u>
<b>FUND REPRESENTED BY :</b>		8,228,747	7,232,632
Accumulated Surplus	7		
		<u>8,228,747</u>	<u>7,232,632</u>

The notes on pages 8 to 12 form part of these financial statements.

Approved on behalf of the Board by:



TSANG Kin Ping  
Director



LEUNG Chat Kan  
Director

NOTES TO FINANCIAL STATEMENTS

31 December 2024

1. COMPANY DETAILS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company is a company incorporated under the Companies Ordinance on 16 January 2020 and with liabilities limited by guarantee with no share capital. In accordance with the Memorandum of Association of the Company, every member shall, in the event of the Company being wound up, contribute to the assets of the Company to the maximum extent of HK\$100. The address of its registered office is G/F., 101, Lai Huen House, Lai Kok Estate, Cheung Sha Wan, Kowloon.

The Company is a non-profit making and an approved charitable organization mainly engaged in providing education and a platform, in order to increase public awareness of rare diseases, strengthen exchanges, support and assist in the study of rare diseases.

The financial statements are presented in Hong Kong Dollars, which are the functional currency of the Company.

Basis of preparation of the financial statements

The Company qualifies for the reporting exemption as a small private Company under Section 359(1)(a) of the Hong Kong Companies Ordinance (Cap. 622). The Company is therefore entitled to prepare and present its financial statements in accordance with the Small and Medium-sized Entity Financial Reporting Standard (the 'SME-FRS') issued by the Hong Kong Institute of Certified Public Accountants.

These financial statements comply with the SME-FRS and have been prepared under the accrual basis of accounting and on the basis that the Company is a going-concern. The measurement base adopted is the historical cost convention.

Revenue recognition

Provided that it is probable that the economic benefits associated with the revenue transaction will flow to the Company and when the revenue and costs, if any, in respect of the transaction can be measured reliably, revenue is recognized as follows:

- a. donations and sponsorship income are recognised when received or receivable;
- b. government subvention is recognised on an accrual basis as according to the agreement with the relevant council;
- c. membership fees income are recognized when received or receivable;
- d. Interest income is recognised on a time proportion basis taking into account the principal outstanding and the interest applicable;
- e. Government subsidy from employment support scheme is recognised when there is a reasonable assurance that it will be received and attached condition are complied with; and
- f. Sundry income is recognised when received or receivable.

NOTES TO FINANCIAL STATEMENTS

31 December 2024

1. COMPANY DETAILS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(continued)

Receivables

Receivables are stated at estimated realizable value after each debt has been considered individually. Where the payment of a debt becomes doubtful a provision is made and taken in the income statement.

Impairment

At each reporting date, fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset (or group of related assets) is estimated and compared with its carrying amount. If an estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognized immediately in surplus or deficit.

If an impairment loss subsequently reverses, the carrying amount of the asset (or group of related assets) is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognized for the asset (group of related assets) in prior years. A reversal of an impairment loss is recognized immediately in surplus or deficit.

Related parties

A party is related to the Company if:

- a. directly, or indirectly through one or more intermediaries, the party:
  - i. controls, is controlled by, or is under common control with, the Company (this includes parents, subsidiaries and fellow subsidiaries);
  - ii. has an interest in the Company that gives it significant influence over the Company; or
  - iii. has joint control over the Company;
- b. the party is an associate of the Company;
- c. the party is a joint venture in which the Company is a venturer;
- d. the party is a member of the key management personnel of the Company or its parent;
- e. the party is a close member of the family of any individual referred to in (a) or (d); or
- f. the party is an entity that is controlled, jointly controlled or significantly influenced by, or for which significant voting power in such entity resides with, directly or indirectly, any individual referred to in (d) or (e).

NOTES TO FINANCIAL STATEMENTS

31 December 2024

1. COMPANY DETAILS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(continued)

Taxation

The Company is a charitable body under Section 88 of the Inland Revenue Ordinance and has been granted tax exemption.

Foreign currencies

The Company's financial records are maintained and its financial statements are stated in Hong Kong dollars.

Monetary assets and liabilities denominated in foreign currencies are translated at the approximate rates of exchange ruling at the end of the reporting period. Foreign currency transactions during the year are recorded at the rates existing on the respective transaction dates. Profits and losses on exchange are dealt with through the income statement.

2. REVENUE AND OTHER INCOME

The Company is engaged in providing education and a platform, in order to increase public awareness of rare diseases, strengthen exchanges, support and assist in the study of rare diseases. Total amounts of revenue and other income are recognised as follows:

	2024 HK\$	2023 HK\$
Revenue		
Donations and sponsorship income	4,759,109	4,566,118
Government subvention		
- from Social Welfare Department	247,870	247,660
Membership fee income	3,220	1,460
	<u>5,010,199</u>	<u>4,815,238</u>
Other income		
Bank interest income	10,457	14,920
Loans interest income from a third party	900,000	600,000
Sundry income	19,037	17,300
	<u>929,494</u>	<u>632,220</u>
	<u>5,939,693</u>	<u>5,447,458</u>



# RARE DISEASE HONG KONG LIMITED

## NOTES TO FINANCIAL STATEMENTS

31 December 2024

### 3. SURPLUS FOR THE YEAR

Surplus for the year is stated after charging the following:

	2024 HK\$	2023 HK\$
Auditor's remuneration	9,120	-
Staff costs		
- Salaries and wages	912,359	756,093
- Mandatory Provident Fund contributions	<u>38,152</u>	<u>25,800</u>

### 4. INCOME TAX EXPENSE

Hong Kong profits tax has not been provided as the Company is exempted from Hong Kong Profits tax under section 88 of the Hong Kong Inland Revenue Ordinance (2023: Same).

### 5. DIRECTORS' EMOLUMENTS

Director's remuneration disclosed pursuant to section 383 of the Hong Kong Companies Ordinance (Cap. 622) and Companies (Disclosure of Information about Benefits of Directors) Regulation (Cap. 622G) for the year is HK\$Nil (2023: HK\$Nil).

### 6. LOANS TO A THIRD PARTY

Two loans (2023: Two Loans) to a third party are unsecured, carry interest at the higher of 20% per annum and gain from algorithm trading in stock and commodities index future; and are repayable on demand upon one month's notice. Subsequent to the end of the reporting year in February, the loans were settled in full.

### 7. ACCUMULATED FUND

	Accumulated Fund HK\$	Total HK\$
Balance at 1 January 2023	6,379,632	6,379,632
Surplus for the year	<u>853,000</u>	<u>853,000</u>
Balance at 31 December 2023	7,232,632	7,232,632
Surplus for the year	<u>996,115</u>	<u>1,005,234</u>
Balance at 31 December 2024	<u>8,228,747</u>	<u>8,237,866</u>



NOTES TO FINANCIAL STATEMENTS

31 December 2024

8. RELATED PARTY TRANSACTIONS

During the year, the Company has undertaken the following transactions with a related party in the normal course of business :

	2024 HK\$	2023 HK\$
<u>Transactions during the year :</u>		
Supportive services fee to a related society	<u>84,000</u>	<u>84,000</u>

9. ACCOUNTS PRESENTATION

Certain prior year comparatives have been reclassified to conform with the current year presentation of the financial statements.

10. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved and authorized for issue by the Council of Management on 21 May 2025.